Findings from a large cohort study suggest that such patients rarely die from antiretroviral hepatotoxicity.
Liver diseases are a leading cause of death in HIV-infected patients, particularly those with hepatitis C virus (HCV) or hepatitis B virus (HBV) coinfection. Although antiretroviral medications can cause hepatotoxicity, the extent to which this complication leads to liver-related mortality in HIV-infected patients who do not have chronic viral hepatitis is not known. To explore this issue, investigators examined the incidence and causes of liver-related deaths in HIV-infected patients without current or previous HCV or HBV coinfection in the DAD cohort.
A total of 22,910 patients were included in the analysis. At study entry, 57% were on antiretroviral therapy (ART), 2.6% had diabetes, and 3.9% were known to have a body-mass index >30 kg/m2;…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)